Breaking News Instant updates and real-time market news.

IPAR

Inter Parfums

$60.60 /

+1.51 (+2.56%)

16:09
01/25/21
01/25
16:09
01/25/21
16:09

Inter Parfums raises FY20 EPS view to $1.15-$1.20 from 80c-84c

Consensus 84c.

IPAR Inter Parfums
$60.60 /

+1.51 (+2.56%)

12/02/20 DA Davidson
Inter Parfums price target lowered to $50 from $55 at DA Davidson
11/11/20 DA Davidson
Inter Parfums price target raised to $55 from $39 at DA Davidson
11/11/20 Citi
Inter Parfums price target raised to $56 from $46 at Citi
08/12/20 BWS Financial
Inter Parfums upgraded to Buy from Neutral at BWS Financial

TODAY'S FREE FLY STORIES

Periodicals
Oracle still on the mend, Barron's says » 11:21
06/19/21
06/19
11:21
06/19/21
11:21
ORCL

Oracle

$76.25 /

-1.31 (-1.69%)

Oracle is in the middle…

Oracle is in the middle of a major business overhaul, reinventing itself for the cloud, Eric Savitz writes in this week's edition of Barron's. The stock has been among the year's best performing tech shares, but the rally may not be over, the author contends. While the stock isn't as cheap as it was in February, this is probably still the beginning of the turnaround at Oracle, not the end, he adds. Reference Link

ShowHide Related Items >><<
ORCL Oracle
$76.25 /

-1.31 (-1.69%)

ORCL Oracle
$76.25 /

-1.31 (-1.69%)

06/16/21 Morgan Stanley
Oracle shares likely range-bound until visibility improves, says Morgan Stanley
06/16/21 Jefferies
Oracle price target raised to $80 from $75 at Jefferies
06/16/21 Monness Crespi
Monness Crespi would be buyers of Oracle on any post-earnings weakness
06/16/21 JPMorgan
Oracle price target raised to $77 from $73 at JPMorgan
ORCL Oracle
$76.25 /

-1.31 (-1.69%)

ORCL Oracle
$76.25 /

-1.31 (-1.69%)

ORCL Oracle
$76.25 /

-1.31 (-1.69%)

ORCL Oracle
$76.25 /

-1.31 (-1.69%)

Periodicals
FedEx stock can still deliver, Barron's says » 11:17
06/19/21
06/19
11:17
06/19/21
11:17
FDX

FedEx

$285.44 /

-2.3 (-0.80%)

, UPS

UPS

$197.69 /

-0.32 (-0.16%)

FedEx (FDX) can charge…

FedEx (FDX) can charge higher fees when demand strengthens, thanks to the duopoly it shares with UPS (UPS), and that should add up to a strong earnings report this coming week, Al Root and Jacob Sonenshine write in this week's edition of Barron's. A big beat and strong guidance will probably be needed to move the stock higher, but if FedEx tops estimates, stock should deliver too, the authors add. Reference Link

ShowHide Related Items >><<
UPS UPS
$197.69 /

-0.32 (-0.16%)

FDX FedEx
$285.44 /

-2.3 (-0.80%)

FDX FedEx
$285.44 /

-2.3 (-0.80%)

06/18/21 Credit Suisse
FedEx price target raised to $364 from $351 at Credit Suisse
06/16/21 Stephens
FedEx price target raised to $360 from $350 at Stephens
06/03/21 Morgan Stanley
FedEx price target raised to $265 from $250 at Morgan Stanley
05/26/21 KeyBanc
FedEx price target raised to $370 from $350 at KeyBanc
UPS UPS
$197.69 /

-0.32 (-0.16%)

06/10/21
Fly Intel: Top five analyst upgrades
06/10/21 BMO Capital
UPS price target raised to $200 from $195 at BMO Capital
06/10/21 Oppenheimer
UPS price target raised to $222 from $210 at Oppenheimer
06/10/21 Stephens
UPS event 'failed to live up to raised investor expectations,' says Stephens
UPS UPS
$197.69 /

-0.32 (-0.16%)

FDX FedEx
$285.44 /

-2.3 (-0.80%)

UPS UPS
$197.69 /

-0.32 (-0.16%)

FDX FedEx
$285.44 /

-2.3 (-0.80%)

UPS UPS
$197.69 /

-0.32 (-0.16%)

FDX FedEx
$285.44 /

-2.3 (-0.80%)

UPS UPS
$197.69 /

-0.32 (-0.16%)

FDX FedEx
$285.44 /

-2.3 (-0.80%)

Periodicals
Reopening might send Six Flags stock vertical, Barron's says » 11:12
06/19/21
06/19
11:12
06/19/21
11:12
SIX

Six Flags

$42.58 /

+0.345 (+0.82%)

With vaccines rolled out…

With vaccines rolled out and pandemic restrictions eased, Americans are eager to make up for lost time, with crowds starting to pack into restaurants, theaters, and other local attractions, Nicholas Jasinski writes in this week's edition of Barron's. Some 1.3 million people flooded into amusement parks operated by Six Flags in the first quarter, versus Wall Street's estimate of just 600,000. That bodes well for Six Flags ' critical summer season, when all 27 of its parks in North America will be open and pandemic capacity limits should be mostly lifted, the author contends. Reference Link

ShowHide Related Items >><<
SIX Six Flags
$42.58 /

+0.345 (+0.82%)

SIX Six Flags
$42.58 /

+0.345 (+0.82%)

05/21/21 Stifel
Stifel ups price target for 'most compelling' theme park Six Flags to $59
04/29/21 KeyBanc
Six Flags price target raised to $55 from $50 at KeyBanc
04/29/21 B. Riley
Six Flags price target raised to $66 from $60 at B. Riley
04/29/21 Truist
Six Flags price target raised to $46 from $42 at Truist
SIX Six Flags
$42.58 /

+0.345 (+0.82%)

SIX Six Flags
$42.58 /

+0.345 (+0.82%)

SIX Six Flags
$42.58 /

+0.345 (+0.82%)

Periodicals
Lennar stock a buy as U.S. faces housing shortage, Barron's says » 11:10
06/19/21
06/19
11:10
06/19/21
11:10
LEN

Lennar

$98.17 /

+3.6 (+3.81%)

The U.S. faces a severe…

The U.S. faces a severe shortage of housing, with one recent study putting the shortfall at about six million units, Andrew Bary writes in this week's edition of Barron's. As one of the country's top home builders, Lennar is well positioned to help fill that gap, the author notes. Reference Link

ShowHide Related Items >><<
LEN Lennar
$98.17 /

+3.6 (+3.81%)

LEN Lennar
$98.17 /

+3.6 (+3.81%)

06/18/21
Fly Intel: Top five analyst upgrades
06/18/21 Evercore ISI
Lennar price target raised to $160 from $121 at Evercore ISI
06/18/21 JPMorgan
JPMorgan upgrades Lennar with transformation not reflected in shares
06/18/21 JMP Securities
Lennar price target raised to $130 from $120 at JMP Securities
LEN Lennar
$98.17 /

+3.6 (+3.81%)

LEN Lennar
$98.17 /

+3.6 (+3.81%)

LEN Lennar
$98.17 /

+3.6 (+3.81%)

LEN Lennar
$98.17 /

+3.6 (+3.81%)

Periodicals
Fully automated car closer than investors think, Barron's says » 11:05
06/19/21
06/19
11:05
06/19/21
11:05
F

Ford

$14.52 /

-0.25 (-1.69%)

, GOOG

Alphabet

$2,510.66 /

-19.215 (-0.76%)

, GOOGL

Alphabet Class A

$2,401.50 /

-32.255 (-1.33%)

, APTV

Aptiv

$147.35 /

-4 (-2.64%)

, GM

General Motors

$58.75 /

-1.31 (-2.18%)

, TSLA

Tesla

$623.36 /

+7.05 (+1.14%)

The sprint to develop a…

The sprint to develop a self-driving car has turned into a slog, one that leaves drivers no closer to buying one than they were five years ago, when Ford Motor (F) promised a car with no steering wheel by 2021, Al Root writes in this week's edition of Barron's. But amid the broken promises, a fully automated car is closer than investors might realize, the author contends. Alphabet (GOOGL), Aptiv (APTV), General Motors (GM) and Tesla (TSLA) are helping make self-driving cars a reality, he adds. Reference Link

ShowHide Related Items >><<
TSLA Tesla
$623.36 /

+7.05 (+1.14%)

GOOG Alphabet
$2,510.66 /

-19.215 (-0.76%)

GM General Motors
$58.75 /

-1.31 (-2.18%)

F Ford
$14.52 /

-0.25 (-1.69%)

APTV Aptiv
$147.35 /

-4 (-2.64%)

F Ford
$14.52 /

-0.25 (-1.69%)

06/04/21 JPMorgan
Ford price target raised to $18 from $16 at JPMorgan
05/28/21 Deutsche Bank
Deutsche starts Lordstown with Hold on 'considerable uncertainty'
05/27/21
Fly Intel: Top five analyst upgrades
05/27/21 Jefferies
Ford 'playing to its strengths' with new EV strategy, says Jefferies
GOOG Alphabet
$2,510.66 /

-19.215 (-0.76%)

06/16/21 Jefferies
Jefferies adds Amazon.com to Franchise Picks list, removes Alphabet
06/11/21 Tigress Financial
Tigress sees Alphabet shares rising to $3,185 in 12 months
06/02/21 KGI Securities
Alphabet initiated with an Outperform at KGI Securities
05/19/21 JPMorgan
Broadcom continues to win AI chip work at Google, says JPMorgan
GOOGL Alphabet Class A
$2,401.50 /

-32.255 (-1.33%)

06/08/21 UBS
Snowflake price target raised to $300 from $275 at UBS
APTV Aptiv
$147.35 /

-4 (-2.64%)

06/02/21 Morgan Stanley
Oil price rise 'significantly improves' EV payback math, says Morgan Stanley
05/13/21 Morgan Stanley
Aptiv price target raised to $205 from $200 at Morgan Stanley
05/10/21 Deutsche Bank
Aptiv price target raised to $165 from $162 at Deutsche Bank
05/07/21 RBC Capital
Aptiv price target raised to $187 from $174 at RBC Capital
GM General Motors
$58.75 /

-1.31 (-2.18%)

06/16/21 Citi
Citi sees path to over $100 per share for GM after guidance and EV spending hike
06/07/21 Barclays
General Motors price target raised to $70 from $66 at Barclays
06/04/21 JPMorgan
General Motors price target raised to $73 from $71 at JPMorgan
TSLA Tesla
$623.36 /

+7.05 (+1.14%)

06/14/21 Canaccord
Tesla price target lowered to $812 from $974 at Canaccord
06/11/21 Credit Suisse
Tesla's Model S Plaid reinforces brand DNA, says Credit Suisse
06/11/21 Goldman Sachs
Goldman says Tesla's Model S Plaid helps illustrate technology leadership
06/08/21 GLJ Research
Tesla's China orders down 69% in Q2 versus Q1, says GLJ Research
TSLA Tesla
$623.36 /

+7.05 (+1.14%)

GOOG Alphabet
$2,510.66 /

-19.215 (-0.76%)

GM General Motors
$58.75 /

-1.31 (-2.18%)

F Ford
$14.52 /

-0.25 (-1.69%)

APTV Aptiv
$147.35 /

-4 (-2.64%)

TSLA Tesla
$623.36 /

+7.05 (+1.14%)

GOOG Alphabet
$2,510.66 /

-19.215 (-0.76%)

GM General Motors
$58.75 /

-1.31 (-2.18%)

F Ford
$14.52 /

-0.25 (-1.69%)

TSLA Tesla
$623.36 /

+7.05 (+1.14%)

GOOG Alphabet
$2,510.66 /

-19.215 (-0.76%)

GM General Motors
$58.75 /

-1.31 (-2.18%)

F Ford
$14.52 /

-0.25 (-1.69%)

APTV Aptiv
$147.35 /

-4 (-2.64%)

TSLA Tesla
$623.36 /

+7.05 (+1.14%)

GOOGL Alphabet Class A
$2,401.50 /

-32.255 (-1.33%)

GOOG Alphabet
$2,510.66 /

-19.215 (-0.76%)

GM General Motors
$58.75 /

-1.31 (-2.18%)

F Ford
$14.52 /

-0.25 (-1.69%)

On The Fly
Opening Day: WalkMe stock price falls following $287M IPO » 08:34
06/19/21
06/19
08:34
06/19/21
08:34
CYT

Cyteir Therapeutics

$17.18 /

+0.18 (+1.06%)

, FEMY

Femasys

$12.45 /

-0.79 (-5.97%)

, AMAM

Ambrx Biopharma

$17.60 /

-0.26 (-1.46%)

, DNAY

Codex DNA

$19.06 /

+0.45 (+2.42%)

, TRMR

Tremor International

$17.92 /

+ (+0.00%)

, ATAI

Atai Life Sciences

$19.50 /

+ (+0.00%)

, IPSC

Century Therapeutics

$22.46 /

+2.98 (+15.30%)

, RERE

AiHuiShou

$16.80 /

-1.56 (-8.50%)

, VERV

Verve Therapeutics

$38.76 /

+7.115 (+22.49%)

, LYEL

Lyell Immunopharma

$16.20 /

-0.6 (-3.57%)

, ISPC

iSpecimen

$7.40 /

+0.29 (+4.08%)

, WKME

WalkMe

$28.83 /

-0.17 (-0.59%)

, MOLN

Molecular Partners

$19.29 /

-0.59 (-2.97%)

, CNVY

Convey Health

$12.20 /

-0.505 (-3.97%)

, ALZN

Alzamend Neuro

$9.01 /

-1.01 (-10.08%)

, FLYW

Flywire

$33.80 /

+1.45 (+4.48%)

, PAY

Paymentus

$29.20 /

-0.53 (-1.78%)

, ZIP

ZipRecruiter

$21.26 /

+0.56 (+2.71%)

, DAWN

Day One Biopharmaceuticals

$21.42 /

+2.1899 (+11.39%)

, FIGS

FIGS

$36.55 /

+0.04 (+0.11%)

, OMIC

Singular Genomics Systems

$23.90 /

-0.34 (-1.40%)

, CNTA

Centessa

$24.87 /

-0.57 (-2.24%)

, DIDI

DiDi

/

+

, QNIU

Qiniu

/

+

, SVFD

Save Foods

$9.44 /

+0.49 (+5.47%)

, RGCB

Regencell Bioscience

/

+

, ELEV

Elevation Oncology

/

+

, CMSL

Camposol

/

+

, DNUT

Krispy Kreme

/

+

, YOU

Clear Secure

/

+

, GS

Goldman Sachs

$348.74 /

-12.86 (-3.56%)

, MS

Morgan Stanley

$84.05 /

-3.86 (-4.39%)

, JPM

JPMorgan

$147.87 /

-3.92 (-2.58%)

, AMZN

Amazon.com

$3,486.78 /

-7.155 (-0.20%)

, F

Ford

$14.52 /

-0.25 (-1.69%)

, SAFO

Save Foods

/

+

, HOOD

Robinhood

/

+

Backed by Insight Venture…

ShowHide Related Items >><<
WKME WalkMe
$28.83 /

-0.17 (-0.59%)

SVFD Save Foods
$9.44 /

+0.49 (+5.47%)

MS Morgan Stanley
$84.05 /

-3.86 (-4.39%)

JPM JPMorgan
$147.87 /

-3.92 (-2.58%)

HOOD Robinhood
/

+

GS Goldman Sachs
$348.74 /

-12.86 (-3.56%)

FLYW Flywire
$33.80 /

+1.45 (+4.48%)

F Ford
$14.52 /

-0.25 (-1.69%)

AMZN Amazon.com
$3,486.78 /

-7.155 (-0.20%)

CYT Cyteir Therapeutics
$17.18 /

+0.18 (+1.06%)

FEMY Femasys
$12.45 /

-0.79 (-5.97%)

AMAM Ambrx Biopharma
$17.60 /

-0.26 (-1.46%)

DNAY Codex DNA
$19.06 /

+0.45 (+2.42%)

TRMR Tremor International
$17.92 /

+ (+0.00%)

ATAI Atai Life Sciences
$19.50 /

+ (+0.00%)

IPSC Century Therapeutics
$22.46 /

+2.98 (+15.30%)

RERE AiHuiShou
$16.80 /

-1.56 (-8.50%)

VERV Verve Therapeutics
$38.76 /

+7.115 (+22.49%)

LYEL Lyell Immunopharma
$16.20 /

-0.6 (-3.57%)

ISPC iSpecimen
$7.40 /

+0.29 (+4.08%)

WKME WalkMe
$28.83 /

-0.17 (-0.59%)

MOLN Molecular Partners
$19.29 /

-0.59 (-2.97%)

CNVY Convey Health
$12.20 /

-0.505 (-3.97%)

ALZN Alzamend Neuro
$9.01 /

-1.01 (-10.08%)

FLYW Flywire
$33.80 /

+1.45 (+4.48%)

PAY Paymentus
$29.20 /

-0.53 (-1.78%)

ZIP ZipRecruiter
$21.26 /

+0.56 (+2.71%)

DAWN Day One Biopharmaceuticals
$21.42 /

+2.1899 (+11.39%)

FIGS FIGS
$36.55 /

+0.04 (+0.11%)

OMIC Singular Genomics Systems
$23.90 /

-0.34 (-1.40%)

CNTA Centessa
$24.87 /

-0.57 (-2.24%)

DIDI DiDi
/

+

QNIU Qiniu
/

+

SVFD Save Foods
$9.44 /

+0.49 (+5.47%)

RGCB Regencell Bioscience
/

+

ELEV Elevation Oncology
/

+

CMSL Camposol
/

+

DNUT Krispy Kreme
/

+

YOU Clear Secure
/

+

GS Goldman Sachs
$348.74 /

-12.86 (-3.56%)

06/17/21 JMP Securities
Goldman Sachs price target raised to $425 from $400 at JMP Securities
06/16/21 JPMorgan
Goldman Sachs price target raised to $452 from $351 at JPMorgan
06/09/21 Jefferies
Jefferies starts 'too cheap' Goldman Sachs at Buy
06/09/21 Jefferies
Goldman Sachs initiated with a Buy at Jefferies
MS Morgan Stanley
$84.05 /

-3.86 (-4.39%)

06/16/21 JPMorgan
Morgan Stanley price target raised to $105 from $85 at JPMorgan
06/09/21 Jefferies
Jefferies starts 'compelling compounder' Morgan Stanley at Buy
06/09/21 Jefferies
Morgan Stanley initiated with a Buy at Jefferies
06/04/21 BofA
Morgan Stanley price target raised to $105 from $92 at BofA
JPM JPMorgan
$147.87 /

-3.92 (-2.58%)

06/15/21 BMO Capital
JPMorgan price target trimmed to $139 at BMO Capital on reduced NII view
06/14/21 Evercore ISI
Synchrony price target raised to $56 from $49 at Evercore ISI
06/08/21 Wells Fargo
JPMorgan price target raised to $200 from $195 at Wells Fargo
05/06/21 JMP Securities
Walker & Dunlop price target raised to $130 from $70 at JMP Securities
AMZN Amazon.com
$3,486.78 /

-7.155 (-0.20%)

06/17/21 Tigress Financial
Amazon shares going to $4,370 in 12 months, says Tigress Financial
06/16/21 JPMorgan
JPMorgan values Amazon Prime at $1,000 per year, 8.5 times actual price
06/16/21 Jefferies
Jefferies adds Amazon.com to Franchise Picks list, removes Alphabet
06/16/21 Pivotal Research
Dish upgraded to Buy from Hold at Pivotal Research
F Ford
$14.52 /

-0.25 (-1.69%)

06/04/21 JPMorgan
Ford price target raised to $18 from $16 at JPMorgan
05/28/21 Deutsche Bank
Deutsche starts Lordstown with Hold on 'considerable uncertainty'
05/27/21
Fly Intel: Top five analyst upgrades
05/27/21 Jefferies
Ford 'playing to its strengths' with new EV strategy, says Jefferies
SAFO Save Foods
/

+

HOOD Robinhood
/

+

MS Morgan Stanley
$84.05 /

-3.86 (-4.39%)

JPM JPMorgan
$147.87 /

-3.92 (-2.58%)

GS Goldman Sachs
$348.74 /

-12.86 (-3.56%)

F Ford
$14.52 /

-0.25 (-1.69%)

AMZN Amazon.com
$3,486.78 /

-7.155 (-0.20%)

  • 18
    Jun
  • 18
    Jun
  • 18
    Jun
  • 18
    Jun
  • 17
    Jun
  • 18
    Jun
  • 18
    Jun
  • 18
    Jun
  • 17
    Jun
  • 16
    Jun
  • 16
    Jun
  • 17
    Jun
  • 16
    Jun
  • 27
    May
  • 28
    May
  • 27
    May
  • 27
    May
  • 26
    May
  • 14
    May
  • 26
    May
  • 26
    May
MS Morgan Stanley
$84.05 /

-3.86 (-4.39%)

JPM JPMorgan
$147.87 /

-3.92 (-2.58%)

HOOD Robinhood
/

+

GS Goldman Sachs
$348.74 /

-12.86 (-3.56%)

F Ford
$14.52 /

-0.25 (-1.69%)

DIDI DiDi
/

+

AMZN Amazon.com
$3,486.78 /

-7.155 (-0.20%)

WKME WalkMe
$28.83 /

-0.17 (-0.59%)

SAFO Save Foods
/

+

MS Morgan Stanley
$84.05 /

-3.86 (-4.39%)

JPM JPMorgan
$147.87 /

-3.92 (-2.58%)

HOOD Robinhood
/

+

GS Goldman Sachs
$348.74 /

-12.86 (-3.56%)

F Ford
$14.52 /

-0.25 (-1.69%)

DIDI DiDi
/

+

DAWN Day One Biopharmaceuticals
$21.42 /

+2.1899 (+11.39%)

AMZN Amazon.com
$3,486.78 /

-7.155 (-0.20%)

MS Morgan Stanley
$84.05 /

-3.86 (-4.39%)

JPM JPMorgan
$147.87 /

-3.92 (-2.58%)

GS Goldman Sachs
$348.74 /

-12.86 (-3.56%)

FIGS FIGS
$36.55 /

+0.04 (+0.11%)

F Ford
$14.52 /

-0.25 (-1.69%)

AMZN Amazon.com
$3,486.78 /

-7.155 (-0.20%)

Hot Stocks
GeoPark responds to letter from former Chair Gerald O'Shaughnessy » 18:05
06/18/21
06/18
18:05
06/18/21
18:05
GPRK

GeoPark

$13.49 /

-0.36 (-2.60%)

GeoPark issued the…

GeoPark issued the following statement in response to the letter sent to the Board by its former Chair Gerald O'Shaughnessy: "Since GeoPark's inception, we have always worked to ensure we have the skills, capabilities and necessary tools to become the leading independent E&P Company in Latin America. As we have grown and matured, we have worked deliberately to strengthen our governance profile and, today, our Board has a majority of independent directors and a newly appointed independent chair, consistent with best practices. We have added two new independent directors in the last 12 months and have nominated a third independent director for election at the upcoming Annual General Meeting. We have also instituted a new Board committee with two independent members to oversee strategic matters. Our Board's continued evolution and diversification in recent years is an important and notable achievement, and one that we expect will help us build and deliver value to all shareholders. It is unfortunate that, after 18 years of service as the Chair of GeoPark's Board, Mr. O'Shaughnessy, 72, has chosen to leave the Board and disparage GeoPark with baseless claims. The Board and the management team are focused on the best interests of the company and our shareholders. We maintain an open dialogue with our shareholders and are always open to opportunities that will create value for all shareholders."

ShowHide Related Items >><<
GPRK GeoPark
$13.49 /

-0.36 (-2.60%)

GPRK GeoPark
$13.49 /

-0.36 (-2.60%)

03/11/21 BMO Capital
GeoPark price target raised to $20 from $15 at BMO Capital
09/24/20 JPMorgan
GeoPark initiated with an Overweight at JPMorgan
06/25/20 Bradesco BBI
GeoPark initiated with an Outperform at Bradesco BBI
Hot Stocks
Newater Technology announces discharge of injunction against going private deal » 18:02
06/18/21
06/18
18:02
06/18/21
18:02
NEWA

Newater Technology

$3.26 /

-0.07 (-2.10%)

Newater Technology…

Newater Technology announced that on June 17, the Commercial Division of the Eastern Caribbean Supreme Court in the British Virgin Islands discharged an injunction that had been obtained on March 16 on an ex parte basis by Fulcan Capital Partners. Fulcan had sought to prevent the company, the members of the board of directors, and Tigerwind Group from taking any steps to proceed with the proposed "going private" merger transaction. In response to the ex parte order, the company applied to discharge the injunction on the basis that Fulcan had breached its duty of full and frank disclosure when applying for the injunction. In discharging the injunction with immediate effect, the BVI Court accepted the company's submissions that the Court had been misled by Fulcan at the ex parte hearing on March 16. In response to the BVI Court's order, Yuebiao Li said, "Although it's too bad that we had to divert precious time and resources to fight this baseless lawsuit, we're glad to have this ex parte injunction behind us."

ShowHide Related Items >><<
NEWA Newater Technology
$3.26 /

-0.07 (-2.10%)

Conference/Events
Vir Biotechnology to host conference call » 17:45
06/18/21
06/18
17:45
06/18/21
17:45
VIR

Vir Biotechnology

$46.11 /

+2.24 (+5.11%)

Management discusses the…

Management discusses the new data on Hepatitis B being presented at the European Association for the Study of the Liver (EASL) Digital International Liver Congress on a conference call to be held on June 25 at 11 am. Webcast Link

ShowHide Related Items >><<
VIR Vir Biotechnology
$46.11 /

+2.24 (+5.11%)

VIR Vir Biotechnology
$46.11 /

+2.24 (+5.11%)

06/03/21 Baird
Vir Biotechnology assumed with a Neutral at Baird
05/27/21 Piper Sandler
Xencorc royalty revenue streams growing, says Piper Sandler
03/11/21 Needham
Vir Biotechnology price target raised to $80 from $75 at Needham
03/08/21 H.C. Wainwright
Vir Biotechnology price target raised to $135 from $125 at H.C. Wainwright
  • 08
    Jul
VIR Vir Biotechnology
$46.11 /

+2.24 (+5.11%)

Conference/Events
Chemours to hold an investor webinar » 17:39
06/18/21
06/18
17:39
06/18/21
17:39
CC

Chemours

$32.85 /

-1.355 (-3.96%)

Management holds an…

Management holds an Advanced Performance Materials Investor Webinar on June 28 at 10 am. Webcast Link

ShowHide Related Items >><<
CC Chemours
$32.85 /

-1.355 (-3.96%)

CC Chemours
$32.85 /

-1.355 (-3.96%)

06/09/21 Wolfe Research
Chemours initiated with an Outperform at Wolfe Research
06/09/21
Fly Intel: Top five analyst upgrades
06/09/21 Goldman Sachs
Chemours upgraded to Buy from Neutral at Goldman Sachs
05/20/21 BofA
BofA starts Chemours at Buy with $42 price target
CC Chemours
$32.85 /

-1.355 (-3.96%)

CC Chemours
$32.85 /

-1.355 (-3.96%)

CC Chemours
$32.85 /

-1.355 (-3.96%)

Conference/Events
Gol Linhas to hold a conference call » 17:34
06/18/21
06/18
17:34
06/18/21
17:34
GOL

Gol Linhas

$9.83 /

+0.015 (+0.15%)

Conference call to…

Conference call to discuss the future of flying in 2021 will be held on June 24 at 2:30 pm. Webcast Link

ShowHide Related Items >><<
GOL Gol Linhas
$9.83 /

+0.015 (+0.15%)

GOL Gol Linhas
$9.83 /

+0.015 (+0.15%)

06/14/21 HSBC
Gol Linhas price target raised to R$26 from R$25 at HSBC
05/05/21 HSBC
Gol Linhas downgraded to Hold from Buy at HSBC
04/11/21 Goldman Sachs
Gol Linhas price target lowered to $9.85 from $11.05 at Goldman Sachs
04/01/21 Itau BBA
Gol Linhas initiated with a Market Perform at Itau BBA
GOL Gol Linhas
$9.83 /

+0.015 (+0.15%)

GOL Gol Linhas
$9.83 /

+0.015 (+0.15%)

Conference/Events
CytoDyn to hold a pharmaceutical update conference call » 17:27
06/18/21
06/18
17:27
06/18/21
17:27
CYDY

CytoDyn

$1.89 /

+0.09 (+5.00%)

President & CEO…

President & CEO Pourhassan, Chairman & CMO Kelly and COO Recknor discuss the results from the unblinded data from COVID-19 long-haulers trial and other regulatory advancements on a conference call to be held on June 21 at 4 pm. Webcast Link

ShowHide Related Items >><<
CYDY CytoDyn
$1.89 /

+0.09 (+5.00%)

CYDY CytoDyn
$1.89 /

+0.09 (+5.00%)

04/06/21
CytoDyn to host conference call
07/06/20 H.C. Wainwright
CytoDyn downgraded to Neutral from Buy at H.C. Wainwright
Conference/Events
Cisco participates in a conference call with Oppenheimer » 17:18
06/18/21
06/18
17:18
06/18/21
17:18
CSCO

Cisco

$52.07 /

-1.065 (-2.00%)

Conference call with SVP…

Conference call with SVP Patel to discuss Cisco's collaboration business, portfolio and competitive advantages will be held on June 24 at 11 am hosted by Oppenheimer.

ShowHide Related Items >><<
CSCO Cisco
$52.07 /

-1.065 (-2.00%)

CSCO Cisco
$52.07 /

-1.065 (-2.00%)

05/21/21
Fly Intel: Top five analyst downgrades
05/21/21 DZ Bank
Cisco downgraded to Hold from Buy at DZ Bank
05/20/21 Morgan Stanley
Cisco tone on growth runway leaves Morgan Stanley confident
05/20/21 Oppenheimer
Cisco price target raised to $55 from $50 at Oppenheimer
CSCO Cisco
$52.07 /

-1.065 (-2.00%)

CSCO Cisco
$52.07 /

-1.065 (-2.00%)

CSCO Cisco
$52.07 /

-1.065 (-2.00%)

CSCO Cisco
$52.07 /

-1.065 (-2.00%)

Conference/Events
Cisco participates in a conference call with Goldman Sachs » 17:10
06/18/21
06/18
17:10
06/18/21
17:10
CSCO

Cisco

$52.07 /

-1.065 (-2.00%)

Management discusses the…

Management discusses the ESG Agenda for 2021 on a conference call to be held on June 22 at 11 am with Goldman Sachs. Webcast Link

ShowHide Related Items >><<
CSCO Cisco
$52.07 /

-1.065 (-2.00%)

CSCO Cisco
$52.07 /

-1.065 (-2.00%)

05/21/21
Fly Intel: Top five analyst downgrades
05/21/21 DZ Bank
Cisco downgraded to Hold from Buy at DZ Bank
05/20/21 Morgan Stanley
Cisco tone on growth runway leaves Morgan Stanley confident
05/20/21 Oppenheimer
Cisco price target raised to $55 from $50 at Oppenheimer
CSCO Cisco
$52.07 /

-1.065 (-2.00%)

CSCO Cisco
$52.07 /

-1.065 (-2.00%)

CSCO Cisco
$52.07 /

-1.065 (-2.00%)

CSCO Cisco
$52.07 /

-1.065 (-2.00%)

Hot Stocks
Climate Change Crisis Real Impact I to transfer listing to Nasdaq from NYSE » 17:02
06/18/21
06/18
17:02
06/18/21
17:02
CLII

Climate Change Crisis Real Impact I

$13.99 /

-0.1 (-0.71%)

Climate Change Crisis…

Climate Change Crisis Real Impact I Acquisition Corporation announced that it intends to voluntarily transfer the listing of its shares of Class A common stock and its warrants to The Nasdaq Global Select Market from the New York Stock Exchange following the completion of its previously announced business combination with EVgo Services, which is expected to close on or around July 1, pending approval by stockholders of CLII at its special meeting for stockholders on June 29. In connection with the closing of the business combination, CLII will change its corporate name to "EVgo Inc." CLII expects its Class A common stock and warrants to commence trading on Nasdaq the day after the closing of the business combination under the symbols "EVGO" and "EVGOW," respectively. The Class A common stock and warrants will continue to trade on the NYSE until the transfer to Nasdaq is complete. The decision to list on Nasdaq was made in connection with the business combination and enables the post-combination company to be listed alongside similar companies that are also listed on Nasdaq. At the closing of the business combination, CLII will also delist its units, Class A common stock and warrants from the NYSE. The Nasdaq listing of the Class A common stock and warrants and the NYSE delisting of the units are subject to the closing of the business combination and the fulfillment of all Nasdaq listing requirements.

ShowHide Related Items >><<
CLII Climate Change Crisis Real Impact I
$13.99 /

-0.1 (-0.71%)

CLII Climate Change Crisis Real Impact I
$13.99 /

-0.1 (-0.71%)

CLII Climate Change Crisis Real Impact I
$13.99 /

-0.1 (-0.71%)

CLII Climate Change Crisis Real Impact I
$13.99 /

-0.1 (-0.71%)

Hot Stocks
BeiGene announces China NMPA approval of BRUKINSA » 16:57
06/18/21
06/18
16:57
06/18/21
16:57
BGNE

BeiGene

$321.99 /

-7.92 (-2.40%)

BeiGene, Ltd. announced…

BeiGene, Ltd. announced that BRUKINSA has received conditional approval from the China National Medical Products Administration for the treatment of adult patients with Waldenstrom's macroglobulinemia who have received at least one prior therapy. The supplemental new drug application was previously granted priority review by the Center for Drug Evaluation of the NMPA in October 2020.

ShowHide Related Items >><<
BGNE BeiGene
$321.99 /

-7.92 (-2.40%)

BGNE BeiGene
$321.99 /

-7.92 (-2.40%)

06/14/21 SVB Leerink
BeiGene price target raised to $417 from $388 at SVB Leerink
03/16/21 HSBC
BeiGene price target raised to $385 from $296 at HSBC
03/08/21 China Renaissance
BeiGene initiated with a Buy at China Renaissance
03/04/21 Goldman Sachs
Five Prime acquisition 'a strategic positive' for Amgen, says Goldman Sachs
BGNE BeiGene
$321.99 /

-7.92 (-2.40%)

  • 02
    Dec
Hot Stocks
CytRx notes Orphazyme regulatory update from FDA on arimoclomol » 16:44
06/18/21
06/18
16:44
06/18/21
16:44
CYTR

CytRx

$1.08 /

-1.74 (-61.70%)

, ORPH

Orphazyme

$7.31 /

-7.24 (-49.76%)

CytRx Corporation (CYTR)…

CytRx Corporation (CYTR) noted that Orphazyme A/S (ORPH) announced it has received a Complete Response Letter, or CRL, from the FDA following its review of the new drug application for arimoclomol, a heat shock protein amplifier intended for the treatment of Niemann-Pick disease type C, or NPC. CytRx's drug candidate, arimoclomol, was sold to Orphazyme in exchange for milestone payments and royalties. Orphazyme's announcement disclosed that the FDA issued the CRL based on needing additional qualitative and quantitative evidence to further substantiate the validity and interpretation of the 5-domain NPC Clinical Severity Scale and, in particular, the swallow domain. Further, the FDA noted in the CRL that additional data are needed to bolster confirmatory evidence beyond the single phase 2/3 clinical trial to support the benefit-risk assessment of the NDA. A primary endpoint of the phase 2/3 clinical trial was progression in disease severity as measured by the 5-domain NPCCSS. This is a disease-specific measure of disease progression consisting of the five clinically most relevant domains to patients with NPC, caregivers and physicians. Orphazyme CEO Christophe Bourdon stated: "We are disheartened by the outcome of the FDA's review, given the urgent need for a new therapeutic option for NPC, but we remain committed to working with the regulators, with the goal of delivering arimoclomol to families managing this challenging disease. We will focus our efforts on pursuing the European regulatory approval, with CHMP opinion expected in Q4 2021 and potential Marketing Authorization in Q1 2022. We are assessing the potential path forward in the U.S. in partnership with the FDA. In the short-term, we will need to reduce our costs substantially and freeze all company efforts not related to clinical and regulatory activities to support approval for NPC." The outcome of the FDA decision has significant influence on Orphazyme's outlook for FY21. Orphazyme's cash position at year-end 2021 is now expected to be approximately $8, where it was previously $56M.

ShowHide Related Items >><<
ORPH Orphazyme
$7.31 /

-7.24 (-49.76%)

CYTR CytRx
$1.08 /

-1.74 (-61.70%)

CYTR CytRx
$1.08 /

-1.74 (-61.70%)

ORPH Orphazyme
$7.31 /

-7.24 (-49.76%)

06/18/21 Cowen
Orphazyme downgraded to Market Perform from Outperform at Cowen
03/30/21 BofA
Orphazyme downgraded to Underperform from Neutral at BofA
03/30/21 BofA
Orphazyme downgraded to Underperform from Neutral at BofA
10/26/20 Guggenheim
Orphazyme initiated with a Buy at Guggenheim
  • 29
    Sep
ORPH Orphazyme
$7.31 /

-7.24 (-49.76%)

ORPH Orphazyme
$7.31 /

-7.24 (-49.76%)

Hot Stocks
Boeing completes successful 737-10 first flight » 16:34
06/18/21
06/18
16:34
06/18/21
16:34
BA

Boeing

$237.44 /

-1.67 (-0.70%)

Boeing's 737-10, the…

Boeing's 737-10, the largest airplane in the 737 MAX family, completed a successful first flight on June 18. The airplane took off from Renton Field in Renton, Washington, at 10:07 a.m. and landed at 12:38 p.m. at Boeing Field in Seattle. The flight was the start of a comprehensive test program for the 737-10. Boeing will work closely with regulators to certify the airplane prior to its scheduled entry into service in 2023.

ShowHide Related Items >><<
BA Boeing
$237.44 /

-1.67 (-0.70%)

BA Boeing
$237.44 /

-1.67 (-0.70%)

06/15/21 Berenberg
Boeing price target raised to $245 from $215 at Berenberg
06/10/21 Jefferies
Boeing shares could move up 5% on China recertification, says Jefferies
06/09/21 Susquehanna
Boeing estimates lowered on light May deliveries, says Susquehanna
06/03/21 Morgan Stanley
Morgan Stanley says recovery tailwinds can offset new launch headwinds at Boeing
BA Boeing
$237.44 /

-1.67 (-0.70%)

BA Boeing
$237.44 /

-1.67 (-0.70%)

BA Boeing
$237.44 /

-1.67 (-0.70%)

BA Boeing
$237.44 /

-1.67 (-0.70%)

Hot Stocks
Pyxis Tankers announces receipt of Nasdaq notice » 16:31
06/18/21
06/18
16:31
06/18/21
16:31
PXS

Pyxis Tankers

/

+

Pyxis Tankers Inc.…

Pyxis Tankers Inc. announced that on June 16, 2021, it received a notification letter from the Nasdaq Stock Market, stating that, for a period of 30 consecutive business days, the company's common shares closed below the minimum bid price of $1.00 per share, as required for continued listing on Nasdaq. The company has until December 13, 2021 to regain compliance with the Minimum Bid Price Requirement. The company can cure this deficiency if the closing bid price of its common shares is $1.00 per share or higher for at least ten consecutive business days during the Compliance Period. The company intends to regain compliance with the minimum bid price requirement within the Compliance Period and is considering all available options, including a reverse stock split. During this time, the company's common shares will continue to be listed and traded on the Nasdaq Capital Market, and this notice will have no effect on the operations of the company's business. If the company does not regain compliance during the Compliance Period, it may be eligible for an additional 180 calendar day compliance period. If the Nasdaq staff concludes that the company will not be able to cure the deficiency or if the company is otherwise not eligible, the company's common shares will be subject to delisting by Nasdaq.

ShowHide Related Items >><<
PXS Pyxis Tankers
/

+

PXS Pyxis Tankers
/

+

02/17/21 Noble Capital
Pyxis Tankers downgraded to Market Perform from Outperform at Noble Capital
PXS Pyxis Tankers
/

+

Options
Preliminary option volume of 48.9M today » 16:30
06/18/21
06/18
16:30
06/18/21
16:30

Preliminary option volume…

Preliminary option volume of 48.9M today is 31% above recent average. Calls led puts 28.73M to 20.13M.

General news
Treasury Market Summary » 16:30
06/18/21
06/18
16:30
06/18/21
16:30
$ECON

Economic Data

/

+

Treasury Market Summary:…

Treasury Market Summary: the markets continued to react to the FOMC's hawkish shift, with comments from St Louis Fed's Bullard the latest catalyst for the day's roiling. He noted in an interview that he filled in a dot for a late 2022 rate hike given his estimate for a 3% rate of core PCE inflation this year and 2.5% for 2022. That added to worries the FOMC could begin its QE taper later this year and begin hiking rates sooner than previously expected. The combination of rising rates and reduced QE as the Fed addresses inflation pressures were the recipe for a hefty bear flattening trade with the front end underperforming. Wall Street was hammered and had one of its worst sessions in some time. Losses were broadbased with the broader indexes underperforming as reflation trades were liquidated. The Dow dropped -1.58% with the S&P 500 down -1.3%, and the NASDAQ off -0.92%.

ShowHide Related Items >><<
$ECON Economic Data
/

+

Conference/Events
Ingevity to hold a virtual investor meeting » 16:28
06/18/21
06/18
16:28
06/18/21
16:28
NGVT

Ingevity

$79.70 /

+0.145 (+0.18%)

Virtual Investor Meeting…

Virtual Investor Meeting to discuss innovative new pathways for activated carbon will be held on June 30 at 10 am. Webcast Link

ShowHide Related Items >><<
NGVT Ingevity
$79.70 /

+0.145 (+0.18%)

NGVT Ingevity
$79.70 /

+0.145 (+0.18%)

05/27/21 Loop Capital
Ingevity price target raised to $85 from $71 at Loop Capital
05/04/21 BMO Capital
Ingevity price target raised to $110 from $100 at BMO Capital
02/11/21 Oppenheimer
Ingevity price target raised to $85 from $75 at Oppenheimer
02/08/21 Loop Capital
Ingevity downgraded to Hold from Buy at Loop Capital
NGVT Ingevity
$79.70 /

+0.145 (+0.18%)

Periodicals
YouTube tells MacRumors iOS app to soon include picture-in-picture support » 16:21
06/18/21
06/18
16:21
06/18/21
16:21
GOOG

Alphabet

$2,510.66 /

-19.215 (-0.76%)

, GOOGL

Alphabet Class A

$2,401.50 /

-32.255 (-1.33%)

, AAPL

Apple

$130.40 /

-1.39 (-1.05%)

YouTube's (GOOG) iOS…

YouTube's (GOOG) iOS and iPadOS (AAPL) apps will soon include picture-in-picture support, allowing all users to close the YouTube app and continuing watching a video in a smaller window, MacRumors' Sami Fathi reports. YouTube told MacRumos that the feature is currently rolling out to all premium iOS subscribers and that a wider launch to all U.S. iOS users will occur soon. Reference Link

ShowHide Related Items >><<
GOOG Alphabet
$2,510.66 /

-19.215 (-0.76%)

AAPL Apple
$130.40 /

-1.39 (-1.05%)

GOOG Alphabet
$2,510.66 /

-19.215 (-0.76%)

06/16/21 Jefferies
Jefferies adds Amazon.com to Franchise Picks list, removes Alphabet
06/11/21 Tigress Financial
Tigress sees Alphabet shares rising to $3,185 in 12 months
06/02/21 KGI Securities
Alphabet initiated with an Outperform at KGI Securities
05/19/21 JPMorgan
Broadcom continues to win AI chip work at Google, says JPMorgan
GOOGL Alphabet Class A
$2,401.50 /

-32.255 (-1.33%)

06/08/21 UBS
Snowflake price target raised to $300 from $275 at UBS
AAPL Apple
$130.40 /

-1.39 (-1.05%)

06/17/21 Loop Capital
Loop Capital starts Cirrus Logic at Buy, cites content gains at Apple
06/11/21 Argus
Apple underperformance due to sector rotation, not misfires, says Argus
06/08/21 RBC Capital
Fisker initiated with an Outperform at RBC Capital
06/08/21 BofA
Apple App store growth decelerating in Q3 to-date, says BofA
GOOG Alphabet
$2,510.66 /

-19.215 (-0.76%)

AAPL Apple
$130.40 /

-1.39 (-1.05%)

GOOG Alphabet
$2,510.66 /

-19.215 (-0.76%)

AAPL Apple
$130.40 /

-1.39 (-1.05%)

GOOG Alphabet
$2,510.66 /

-19.215 (-0.76%)

AAPL Apple
$130.40 /

-1.39 (-1.05%)

GOOGL Alphabet Class A
$2,401.50 /

-32.255 (-1.33%)

GOOG Alphabet
$2,510.66 /

-19.215 (-0.76%)

AAPL Apple
$130.40 /

-1.39 (-1.05%)

Options
Closing CBOE SPX and VIX Index summary for June 18th » 16:20
06/18/21
06/18
16:20
06/18/21
16:20
VIX

Volatility Index S&P 500 Options

/

+

The CBOE Volatility Index…

The CBOE Volatility Index (VIX), the SPX option derived measure of implied volatility, lifted 2.95 today to close at 20.70, while the underlying SPX index lost 55.41 to close at $4166.45, a 1.31% decline. 468,689 VIX option contracts traded, 87.51% of the typical daily volume for the product. Calls made up 53.8% of the volume.

ShowHide Related Items >><<
VIX Volatility Index S&P 500 Options
/

+

Technical Analysis
NASDAQ market internals summary » 16:17
06/18/21
06/18
16:17
06/18/21
16:17
$NSD

NASDAQ Market Internals

/

+

Volume was above average…

Volume was above average for this time of day. Breadth was mixed with issues and volume bearish while new highs to new lows were bullish (positive divergence). Advancing Issues: 1276 / Declining Issues: 3032 -- for a ratio of 0.4 to 1. Advancing Volume: 2,005,999,000 / Declining Volume: 3,778,342,000 -- for a ratio of 0.5 to 1. New 52-Week Highs: 93 / New 52-Week Lows: 64.

ShowHide Related Items >><<
$NSD NASDAQ Market Internals
/

+

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.